Jennifer Buell· @jbuell01 · X·· 2026-04-21评分60
正文 · 原文
At #AACR26, Dr. Sam Cytryn
@MSKCancerCenter
reports INKT+BOT/BAL and chemo in r/r GEJ:
- 20% survival beyond 3 years in r/r GEJ
- Immune activation across assays
- Activity in active liver mets
In refractory disease, durability defines impact.
@MiNK_iNKT
@Agenus_Bio
热度 15 · 11 赞 · 0 回复 · 4 转发
来源:Jennifer Buell · x.com
